This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
Zacks News
How Will Biotech ETFs React to These Q3 Earnings Release?
by Sweta Jaiswal, FRM
Let's take a look at some ETFs with exposure to major players in the U.S. biotech industry, post their third-quarter earnings releases amid the coronavirus crisis.
Moderna Expects COVID-19 Vaccine Data in November: ETFs to Gain
by Sweta Jaiswal, FRM
Positive comment on coronavirus vaccine progress from Moderna's (MRNA) CEO during The Wall Street Journal's annual Tech Live conference has gained investors attention and raised vaccine optimism.
Biotech ETFs to Shine on Coronavirus Antibodies Progress
by Sweta Jaiswal, FRM
With Regeneron Pharmaceuticals and Eli Lilly & Company requesting the FDA for an Emergency Use Authorization for their antibody therapy treatments, the biotech space is filled with optimism.
Biotech ETFs to Gain on Trump's COVID-19 Treatment Protocol
by Sweta Jaiswal, FRM
The progress in Trump's health condition and his treatment protocols are continuously under the purview of market participants and are impacting Wall Street movements.
Top-Performing Biotech ETFs Amid the Coronavirus Crisis
by Sweta Jaiswal, FRM
The race to introduce vaccine and treatment of coronavirus is opening up opportunities, making the biotech sector a prospective space for investments.
Biotech ETFs in Focus as the COVID-19 Vaccine Race Intensifies
by Sweta Jaiswal, FRM
Johnson & Johnson's entry into the late-stage trials has increased optimism in the coronavirus vaccine development.
ETFs to Gain as AstraZeneca Resumes Coronavirus Vaccine Trial
by Sweta Jaiswal, FRM
AstraZeneca's resumption of the late-stage trials can revive investors optimism surrounding the coronavirus vaccine development.
How Will Biotech ETFs React to Vaccine Makers' Safety Pledge?
by Sweta Jaiswal, FRM
Nine vaccine developers have jointly pledged to observe high ethical standards in conducting clinical studies and manufacturing of vaccines.
Will Novavax ETFs Gain on Coronavirus Vaccine Progress?
by Sweta Jaiswal, FRM
Investors are closely tracking the progress in the coronavirus vaccine development amid the coronavirus outbreak.
Biotech ETFs to Shine Bright on Coronavirus Vaccine Progress
by Sweta Jaiswal, FRM
AstraZeneca's initiation of a phase III study has heated up competition to bring a coronavirus vaccine to the markets.
Moderna ETFs to Gain on New Positive COVID-19 Vaccine Data
by Sweta Jaiswal, FRM
Per the latest data from an early stage clinical trial, Moderna's experimental coronavirus vaccine is successfully producing neutralizing antibodies and T-cells in older adults.
Moderna ETFs to Shine on U.S. Contracts for Coronavirus Vaccine
by Sweta Jaiswal, FRM
Moderna has inked a $1.5-billion coronavirus vaccine supply agreement with the U.S. government.
How Will Biotech ETFs React to Q2 Earnings Release?
by Sweta Jaiswal, FRM
Let's take a look at some ETFs with exposure to major players in the U.S. biotech industry, post their Q2 earnings releases amid the coronavirus crisis.
Moderna Turns Red Hot: Biotech ETFs to Bet On
by Sweta Killa
Moderna skyrocketed 245% since it announced its COVID-19 vaccine candidate mRNA-1273 on Feb 10. The solid run is likely to continue as most of the analysts are optimistic on the stock.
Late-Stage Coronavirus Vaccine Trials Begin: Biotech ETFs to Gain
by Sweta Jaiswal, FRM
Two major vaccine developers' entrance into the final stage trials is expected to boost investor optimism.
Biotech ETFs to Gain on Coronavirus Vaccine Progress
by Sweta Jaiswal, FRM
The race to find a coronavirus vaccine is heating up as the latest positive data from progress in trials are being published.
Moderna Inches Closer to Coronavirus Vaccine: ETFs to Shine
by Sweta Jaiswal, FRM
Moderna plans to begin the Phase 3 study of mRNA-1273 this month.
How to Tap Red-Hot Moderna Stock With ETFs
by Sweta Killa
Moderna shares have surged more than 280% so far this year on the positive development of coronavirus vaccine.
Expect Further Rally in Nasdaq-100 ETFs as Moderna Joins
by Sanghamitra Saha
Moderna shares have gained a whopping 283.6% this year due to successful early-stage clinical trials for COVID-19 vaccine, winning a place on the Nasdaq-100 with the company's sheer success.
Biotech ETFs to Shine on Pfizer's Coronavirus Vaccine Progress
by Sweta Jaiswal, FRM
Two out of four of Pfizer's coronavirus vaccine candidates, BNT162b1 and BNT162b2, have been granted the 'fast track' designation by the FDA.
Biotech ETFs to Gain as Coronavirus Vaccine Hopes Strengthen
by Sweta Jaiswal, FRM
As the coronavirus outbreak continues to aggravate, investors are eyeing developments in vaccine or treatments to combat the pandemic.
Moderna a Step Closer to Coronavirus Vaccine: ETFs to Gain
by Sweta Jaiswal, FRM
Moderna informs that the final-stage trial's primary aim will be to prevent the spread of coronavirus.
How Are Biotech ETFs Reacting to Coronavirus Treatment News?
by Sweta Jaiswal, FRM
Here we take a look at how the latest updates on drugs, antibody therapies and vaccines targeted at winning the coronavirus battle can affect biotech ETFs.
These ETF Areas Make Great Investment Choices in June
by Sweta Jaiswal, FRM
Here we highlight some ETF areas that will make interesting investment options for investors amid the coronavirus crisis.
Biotech ETFs Soaring on COVID-19 Vaccine Progress
by Sweta Jaiswal, FRM
Novavax's latest progress in the Covid-19 vaccine development brings optimism to the Wall Street.